Pathios Therapeutics is a biotech company focused on the development of therapies for autoimmune diseases and cancer.
Pathios Therapeutics has raised $25.0M in total funding. The most recent round was Series B. The last funding was announced in April 2024.
Pathios Therapeutics's investors include Brandon Capital, Bristol-Myers Squibb, Innovate UK, Canaan Partners, Medical Research Commercialisation Fund (MRCF).
Pathios Therapeutics is headquartered in Oxford, United Kingdom.
Pathios Therapeutics is a biotech company focused on the development of therapies for autoimmune diseases and cancer.
Pathios Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Pathios Therapeutics — Funding & Investors." VCBacked, April 18, 2024, https://www.vcbacked.co/company/pathios-therapeutics. Accessed September 15, 2026.
VCBacked. (2024). Pathios Therapeutics — Funding & Investors. Retrieved September 15, 2026, from https://www.vcbacked.co/company/pathios-therapeutics
{{cite web |title=Pathios Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/pathios-therapeutics |website=VCBacked |access-date=September 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated